Untersuchungen zum Effekt von ASS-Einnahme auf die in vitro Qualität von Thrombozyten bei der Thrombozytapherese und während der 5-Tages-Lagerung von Thrombozytenkonzentraten
Loading...
Files
Date
Authors
Publisher
Philipps-Universität Marburg
Abstract
Preventing the activation of PLTs may
ameliorate (or mitigate) the PLT storage lesion (PSL),
which encloses all structural and biochemical changes
caused by collection, processing, and storage of PLT
concentrates (PCs). Partial inhibition of PLT function due
to ingestion of aspirin (ASA) by blood donors reduces the
functional activity of the collected PLTs, however, by
preventing premature PLT activation, it might reduce the PSL as well.
STUDY DESIGN AND METHODS:
In a randomized crossover study, 10 healthy donors donated two singledonor
PCs (SDPCs) each, taking 500 mg ASA 12 hours
before one of the aphereses (Group A) and taking no
medication before the other donation (Group B). In-vitro
tests of PLT function were performed in donors before and
after apheresis and in SDPCs during storage (Days 1, 3,and 5).
RESULTS:
ASA ingestion resulted in a significant
decrease of induced PLT aggregation in donors (p <0.005) and SDPCs on Day 1 (p<0.01). TRAP-6–induced expression of p-selectin (CD62p) was significantly
reduced in Group A SDPCs only on Day 1 (p<0.02).
There were no significant differences of in-vitro function
(LDH, lactate, pH, morphology score, CD62p expression,
fibrinogen binding) between Group A and B (SDPCs and
donors). Apheresis did not result in a significant activation
of PLTs in donors or SDPCs.
CONCLUSIONS:
These limited data do not show adetectable beneficial effect of ASA ingestion on the PSL
but do suggest that ASA ingestion before apheresis may
not be detrimental to the clinical effectiveness of the
stored product.
Review
Metadata
License
This item has been published with the following license: In Copyright